GHK-Cu occupies an unusual place among research peptides. It is a naturally occurring human molecule, it has decades of published literature behind it, and it is one of the few peptides that is legally sold to consumers in the UK, albeit only in one specific form: as an ingredient in topical cosmetics. That last point causes a lot of confusion about what the research actually supports and what the law allows.
This guide sets out what GHK-Cu is, how it is thought to work, what the evidence does and does not show, how it compares with AHK-Cu, and its UK legal position in 2026.
Important: GHK-Cu is not a licensed medicine. Nothing in this article constitutes medical advice or an instruction for human use.
What Is GHK-Cu?
GHK is a tripeptide, three amino acids long: glycine, histidine and lysine (Gly-His-Lys). It binds copper(II) ions with high affinity, and the copper complex is what is referred to as GHK-Cu. The peptide was first isolated from human plasma in 1973 by Loren Pickart, who noticed that plasma from young donors had effects on liver tissue in culture that plasma from older donors lacked, and traced the difference to this small peptide.
Key characteristics:
- Endogenous. GHK is found naturally in human plasma, saliva and urine. Reported plasma concentrations decline substantially with age, which is one reason it attracted interest in ageing research.
- Copper-binding. Much of its proposed activity is attributed to its ability to deliver copper to cells and to modulate copper-dependent enzymes.
- Well characterised. Because it is short and simple to synthesise, GHK-Cu has been studied for over fifty years and has a larger literature than most research peptides.
GHK-Cu is sold as a research compound by chemical suppliers and, separately, as an ingredient in cosmetic serums and creams under the name copper tripeptide-1.
How Is GHK-Cu Thought to Work?
Several mechanisms have been proposed, almost all from in-vitro and animal work.
Collagen and extracellular matrix
In fibroblast cultures GHK-Cu has been associated with increased synthesis of collagen, elastin and glycosaminoglycans, and with modulation of matrix metalloproteinases, the enzymes that break connective tissue down. This is the basis for its use in cosmetic formulations aimed at skin appearance.
Wound healing models
Animal studies, mainly in rodents and rabbits, have reported faster closure of wounds treated with GHK-Cu, with increased blood-vessel formation and recruitment of immune cells to the wound site.
Gene expression
A widely cited line of work used the Broad Institute's Connectivity Map to compare the gene-expression signature of GHK-Cu in cultured cells against disease signatures. The authors reported that GHK-Cu altered expression of a large number of genes, and argued this could explain its broad range of reported effects. This is a computational and in-vitro finding; it has not been tested in controlled human trials.
Antioxidant and anti-inflammatory activity
GHK-Cu has been reported to reduce markers of oxidative stress and inflammatory cytokines in cell culture and in some animal models, including lung-injury models.
What this does and doesn't tell us
The mechanisms are plausible and the in-vitro data are extensive. But cell-culture effects at particular concentrations do not translate directly to effects in a living organism, and the human evidence, discussed next, is almost entirely limited to topical application.
What Does the Research Say?
Tier 1: In-vitro and animal studies (extensive)
Hundreds of papers over five decades. Consistent reports of effects on fibroblasts, collagen production, wound closure and gene expression. As with many research peptides, a substantial fraction of the literature comes from a small number of groups, and Pickart's own work accounts for a large share of it.
Tier 2: Human data (limited to topical use)
There are a number of small human studies of cosmetic products containing GHK-Cu applied to skin, typically measuring wrinkle depth, skin density or elasticity over 8 to 12 weeks. Several report improvements versus placebo or versus vehicle. These studies are generally small, often industry-sponsored, and use finished cosmetic formulations rather than the peptide alone, which makes it hard to isolate the contribution of GHK-Cu.
There are no published randomised controlled trials of GHK-Cu administered by injection or any other systemic route in humans. Claims about systemic effects rest on animal data and extrapolation.
Tier 3: Reviews
Reviews generally describe GHK-Cu as a well-tolerated cosmetic ingredient with plausible mechanisms and an interesting research profile, while noting the lack of rigorous human trials beyond topical application.
The bottom line on evidence
GHK-Cu has the strongest human evidence of any peptide in a typical research catalogue, but that evidence is narrow: topical cosmetic use, for skin appearance, in small studies. Everything else is preclinical.
GHK-Cu vs AHK-Cu
AHK-Cu is a related copper tripeptide (alanine-histidine-lysine) that is often discussed alongside GHK-Cu. They are different molecules with different, and much smaller, evidence bases.
| GHK-Cu | AHK-Cu | |
|---|---|---|
| Sequence | Gly-His-Lys, copper complex | Ala-His-Lys, copper complex |
| Origin | Naturally occurring in human plasma | Synthetic analogue |
| Main research focus | Skin, wound healing, collagen, gene expression | Hair follicle cells, dermal papilla, VEGF signalling |
| Human data | Small topical cosmetic studies | Very limited; mostly in-vitro |
| Literature size | Large, five decades | Small |
| UK status | Cosmetic ingredient (topical); research use otherwise | Research use only |
In brief: GHK-Cu is the well-studied parent compound; AHK-Cu is a less-characterised variant that has mainly been examined in hair-follicle cell cultures. They are not interchangeable and there is no controlled research comparing them.
Is GHK-Cu Legal in the UK?
GHK-Cu has a clearer legal position than most research peptides, because one use is explicitly regulated as a cosmetic.
As a cosmetic ingredient
Copper tripeptide-1 is a permitted cosmetic ingredient under the UK Cosmetics Regulation. Finished cosmetic products containing it can be lawfully sold to consumers for topical application, provided the product is notified, safety-assessed and labelled in accordance with cosmetics law, and provided no medicinal claims are made. A cosmetic can claim to improve the appearance of skin; it cannot claim to treat a condition.
As a research compound
GHK-Cu powder sold as a laboratory reagent is not a cosmetic and not a medicine. It falls under the same framework as other research peptides: lawful to sell and buy for in-vitro research, provided it is not presented for human use. It is not a controlled substance under the Misuse of Drugs Act 1971.
As a medicine
GHK-Cu holds no marketing authorisation from the MHRA. Selling it with therapeutic claims, or in a form presented for injection or ingestion by a person, would bring it within the Human Medicines Regulations 2012 as an unlicensed medicine. The research-use designation offers no protection once medicinal claims or human-use instructions are attached.
Sport
GHK-Cu is not named on the WADA Prohibited List. Athletes should note that the list includes a general category for non-approved substances and should take their own advice.
Summary
| Question | Answer |
|---|---|
| Is it a controlled drug? | No |
| Is it a licensed medicine? | No |
| Can it be sold in cosmetics? | Yes, as copper tripeptide-1, under cosmetics law |
| Can it be bought for laboratory research? | Yes, from suppliers selling it research-use-only |
| Can it be sold or marketed for injection or ingestion? | No |
GHK-Cu FAQs
Is GHK-Cu the same as copper peptide?
"Copper peptide" in cosmetics almost always means GHK-Cu (copper tripeptide-1). Other copper-binding peptides exist, including AHK-Cu, but GHK-Cu is the one with the literature and the cosmetic history.
Why does GHK-Cu turn blue?
The copper(II) complex is blue. Powder and solutions of GHK-Cu are characteristically blue to blue-violet; a colourless GHK-Cu solution suggests the copper is absent or has been reduced.
Has GHK-Cu been proven to work in humans?
Small studies of topical cosmetic products report improvements in skin appearance. There is no controlled human evidence for any other route or effect.
Is GHK-Cu legal to buy in the UK?
Yes: in cosmetic products for topical use, and as a research reagent for laboratory use. It is not legal to sell or market it for injection or ingestion.
Is GHK-Cu banned in sport?
It is not specifically listed by WADA. Athletes should seek their own advice given the list's general provisions.
What is the difference between GHK-Cu and AHK-Cu?
One amino acid (glycine versus alanine at the first position), a very different evidence base, and a different research focus. GHK-Cu is the well-studied compound; AHK-Cu is a variant examined mainly in hair-follicle cell cultures.
This article is for informational purposes only. It does not constitute medical, legal or professional advice. GHK-Cu sold as a research compound is intended for in-vitro laboratory use and is not licensed for human use.
